A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome

A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome - Rituximab to refractory nephrotic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021143

Enrollment

Registered

2016-02-23

Start date

2016-02-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory nephrotic syndrome

Interventions

an intravenous dose of 375 mg per 1 square meter (maximum 500 mg) once weekly for 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Steroid dependent nephrotic syndrome 2. Frequently relapsing nephrotic syndrome 3. Refractory nephrotic syndrome

Exclusion criteria

Exclusion criteria: 1. Severe hypersensitivity to the component of rituximab or products derived from mouse protein. 2. Positive serology for HBs antigen or HBv-DNA 3. Active infection

Design outcomes

Primary

Measure	Time frame
The dose of glucocorticoids and immunosuppressive drugs after 3 months	—

Secondary

Measure	Time frame
1. number of relapses per person-year 2. Urinary protein and serum albumin (3 months and 1 year 3. The dose of glucocorticoids and immunosuppressive drugs after 1 year 4. Severe adverse events during 1 year	—

Countries

Japan

Contacts

Public ContactHasegawa Midori

Fujita Health University School of Medicine Department of Nephrology

mhase@fujita-hu.ac.jp0562-93-9245

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026